A retrospective cohort study analyzed post-operative outcomes following primary total knee or hip arthroplasty (TKA/THA) comparing patients receiving tirzepatide, a dual GIP/GLP-1 receptor agonist, versus those receiving semaglutide, a selective GLP-1 receptor agonist.
Key Clinical Findings
The study utilized the TriNetX US Collaborative Network and included adults undergoing TKA or THA with at least two coded prescription fills for either tirzepatide or semaglutide within six months of surgery. Patients taking both agents were excluded. The cohorts were propensity score matched, with 2,858 patients in each group.
Long-Term Outcomes
Outcomes were assessed at 90 days, 1 year, and 2 years. Initially, no significant differences were observed in surgical, medical, or implant-related outcomes at 90 days and 1 year. However, at 2 years, exposure to tirzepatide was associated with reduced odds of mechanical complications (OR 0.64, 95% CI 0.42 to 0.96) and periprosthetic joint infection (PJI) (OR 0.64, 95% CI 0.41 to 0.999; P = 0.048). There was no significant difference in reoperation rates (OR 0.68, 95% CI 0.43 to 1.08).
Of 669,698 patients who underwent primary TKA or THA, 8,797 (1.3%) had ≥2 tirzepatide or semaglutide prescriptions.